-Hepatocyte growth factor (HGF) is critical for tissue homeostasis and repair in many organs including the lung, heart, kidney, liver, nervous system, and skin. HGF is a heterodimeric protein containing 20 disulfide bonds distributed among an amino-terminal hairpin, four kringle domains, and a serine protease-like domain. Due to its complex structure, recombinant production of HGF in prokaryotes requires denaturation and refolding, processes that are impractical for large-scale manufacture. Thus, pharmaceutical quantities of HGF are not available despite its potential applications. A fragment of the Listeria monocytogenes internalin B protein from amino acids 36 -321 (InlB 36 -321) was demonstrated to bind to and partially activate the HGF receptor Met. InlB 36 -321 has a stable ␤-sheet structure and is easily produced in its native conformation by Escherichia coli. We cloned InlB 36 -321 (1ϫInlB36-321) and engineered a head-to-tail repeat of InlB 36 -321 with a linker peptide (2ϫInlB36-321); 1ϫInlB36-321 and 2ϫInlB 36 -321 were purified from E. coli. Both 1ϫ and 2ϫInlB36-321 activated the Met tyrosine kinase. We subsequently compared signal transduction of the two proteins in primary lung endothelial cells. 2ϫInlB 36 -321 activated ERK1/2, STAT3, and phosphatidylinositol 3-kinase/Akt pathways, whereas 1ϫInlB 36 -321 activated only STAT3 and ERK1/2. The 2ϫInlB 36 -321 promoted improved motility compared with 1ϫInlB 36 -321 and additionally stimulated proliferation equivalent to full-length HGF. Both the 1ϫ and 2ϫInlB 36 -321 prevented apoptosis by the profibrotic peptide angiotensin II in cell culture and ex vivo lung slice cultures.
exogenously as a protein or via gene therapy has been demonstrated to promote normal tissue repair and prevent fibrotic remodeling and scarring (20, 27, 41, 46, 57, 61, 62) .
HGF signaling through its receptor Met is considered an important factor for epithelial repair following lung injury (10) . Defects in HGF signaling have been observed in patients with IPF and in patients with systemic sclerosis, who are susceptible to lung fibrosis (5, 23, 39) . Abnormally low levels of HGF have been correlated with increased severity of pulmonary diseases in preterm infants (33) . HGF treatment has been shown to mitigate lung injury and induce normal tissue repair in a variety of experimental animal models including: 1) fibrotic remodeling in response to bleomycin (66) ; 2) allergic airway inflammation in response to ovalbumin (50); 3) acute lung injury induced by intratracheal infusion of HCl (49); 4) acute respiratory distress syndrome following treatment with LPS (25); and 5) elastase-induced emphysema (56) . The efficacy of HGF in mitigating such a wide variety of lung injuries illustrates the overall importance of HGF in normal alveolar repair processes.
HGF is synthesized in cells as a 90-kDa polypeptide chain containing an amino-terminal hairpin, four kringle domains, and a serine protease-like domain. Functionally active HGF protein requires correct folding in a conformation that contains 20 disulfide bonds (53) . HGF binding to its receptor Met, a tyrosine kinase receptor with a single transmembrane domain, results in activation of multiple downstream signaling pathways, most notably the p42/p44 MAPK (ERK1/2), STAT3, and PI3K/Akt pathways. We and others have demonstrated that the combination of these signaling events are required for motility, anti-apoptotic activity, and proliferation in cell culture (12) .
Despite the obvious potential therapeutic uses of HGF, the complexity of the full-length HGF protein structure has severely hindered its development as a pharmaceutical agent. Attempts have been made to use smaller fragments of the HGF molecule, such as NK1 or NK2, that are naturally occurring isoforms of HGF containing only the amino-terminal hairpin and the first kringle or first and second kringle domains, respectively (8) . Although NK1 can induce motility, survival, and proliferation, its potency is lower than that of full-length HGF (8) . NK2 activation of Met results in cell motility in transformed cells, but not cell survival or proliferation (12) . But most importantly, despite their smaller size, large-scale production of biologically active NK1 and NK2 has not yet succeeded, as their synthesis in bacteria still requires timeconsuming and expensive steps of refolding and renaturation to attain correct conformation (58) .
Other proteins, such as the internalin B (InlB) protein produced by Listeria monocytogenes, have been identified that bind to Met. The process of L. monocytogenes invasion of a host cell involves a "zipper" mechanism, in which the bacterium attaches to the host cell membrane and triggers a series of intracellular signaling cascades (63) . The InlB protein of L. monocytogenes is one of two proteins found to participate in binding of the bacterium to the host cell. Full-length InlB was found to partially activate the Met receptor, resulting in ERK1/2 pathway activation (63) . In some cells, full-length InlB was also shown to activate the phosphatidylinositol 3-kinase (PI3K)/Akt pathway (3, 6) . Met binding and signal transduction by InlB correlated with increased invasiveness of the pathogen (2, 24, 63) . The structure of the internalin domain of InlB (amino acids 36 -321) was analyzed by crystallography in complex with a portion of the extracellular region of the Met receptor (the semaphorin, the cysteine-rich, and first two Iglike domains; amino acids 25-741) (48) . Structural analysis revealed that the primary affinity-determining contacts occur between the concave face of the InlB 36 -321 leucine-rich repeat (LLR) region and the Ig1 domain of Met. The InlB 36 -321 fragment makes secondary contacts through its interrepeat (IR) region with the semaphorin domain of Met, and binding in this region is thought to be required for receptor activation (48) . Unlike full-length InlB or full-length HGF, the InlB 36 -321 fragment failed to induce DNA synthesis in MDCK cells (48) . While the work described here was in progress, a stable dimer of InlB 36 -321 was produced by engineering disulfide bonds centered on the convex face of the LRR helix, allowing the formation of an anti-parallel arrangement of two InlB 36 -321 fragments (15) . The crystal structure was solved with the Met fragment demonstrating that a symmetrical dimer of InlB 36 -321 assembled having a stoichiometry of 2:2 with the Met ectodomain. Furthermore, the InlB 36 -321 dimer induced motility and proliferation in MDCK cells.
Here we show that the InlB 36 -321 fragment of L. monocytogenes (1ϫInlB 36 -321 ) induces activation of ERK1/2 and STAT3 in primary lung endothelial cells and has anti-apoptotic and motogenic activity. We constructed an expression vector encoding a head-to-tail repeat of InlB 36 -321 (2ϫInlB 36 -321 ) with a short peptide linker. We demonstrate that the resulting tandem dimer 2ϫInlB 36 -321 induces signaling through ERK1/2, PI3K/Akt, and STAT3 pathways, and has improved migratory activity compared with the 1ϫInlB 36 -321 . The 2ϫInlB 36 -321 also induces proliferation in primary lung cells equivalent to full-length HGF. We report for the first time these activities of InlB associated with mitogenesis, cell survival, and motogenesis in primary cells.
MATERIALS AND METHODS
Reagents. Genomic DNA from L. monocytogenes was the generous gift of Dr. Laurel Lenz (National Jewish Medical and Research Center, Univ. of Colorado, Denver). Phospho-ERK1/2 antibody was purchased from Signal Transduction Laboratories (Beverly MA); anti-ERK1/2 was from Upstate Biotech (Charlottesville, VA); phospho-Akt, total Akt, phospho-STAT3, total STAT3, active caspase 3, and uncleaved caspase 3 antibodies were purchased from Cell Signaling Technology (Danvers, MA). The primary anti-phosphotyrosine antibody 4G10 was purchased from Millipore (Billerica, MA). Angiotensin II (Ang II) peptide was purchased from Bachem (Torrance, CA). The primary antibody ␣-tubulin was purchased from Sigma (St. Louis, MO). ␤-actin antibody was from Santa Cruz Biotechnology (Santa Cruz, CA). 36 -321 . The InlB sequence from amino acid 36 -321 (GenBank acc. no. DQ132796, nucleotide sequence from 106 to 963) was amplified using the Pfu DNA polymerase (Stratagene, La Jolla, CA), L. monocytogenes genomic DNA, and the primers: forward 5=-ggg aac acg tgG AGA CTA TCA CCG TGT CAA C-3= and reverse 5=-cgg gat cct att aCT CTT TCA GTG GTT GGG TTA CT-3=, with uppercase bases corresponding to InlB gene sequences and lowercase bases indicating 5=-extensions with restriction enzyme sites (bold) for PmlI and BamHI, respectively. The monomeric InlB fragment is designated as 1ϫInlB 36 -321. A tandem repeat was constructed of the InlB36-321 fragment (2ϫInlB36-321) by joining the two AclI cut PCR products, which were amplified using the forward or reverse primers described previously and a second reverse primer 5=-ttt gga tcc aac gtt CTC TTT CAG TGG TTG GGT TAC TTC-3= or a second forward primer 5=-ttt gga tcc aac gtt CTC TTT CAG TGG TTG GGT TAC TTC-3=, respectively, both containing the AclI site (bold). PCR condition was as follows: an initial denaturation of 94°C for 3 min; 10 cycles of 94°C for 30 s, 55°C for 30 s, and 72°C for 2.5 min; 25 cycles of 94°C for 30 s, 55°C for 30 s, and 72°C for 2 min; with a final extension of 5 min at 72°C. The PCR products were cloned into the pET302/NTHis vector (Invitrogen, Carlsbad, CA) using the PmlI and BamHI sites, and insertions were verified by DNA sequencing.
Cloning and expression of the L. monocytogenes InlB
The NH 2-terminal 6ϫ His-tagged recombinant 1ϫInlB36-321 and 2ϫInlB36-321 were introduced into E. coli BL21-CodonPlus cells according to the manufacturer's protocol (Stratagene, La Jolla, CA). Protein expression was induced at bacterial cell growth of OD600 ϭ 0.6 -0.8 with 1 mM isopropyl ␤-D-1-thiogalactopyranoside for 3 h at 37°C. Bacterial cells were collected by 10 min of centrifugation at 4,000 g, washed with lysis buffer (50 mM NaH2PO4, 300 mM NaCl, 10 mM imidazole, pH 8.0), and stored overnight at Ϫ20°C. The next day, cells were resuspended in lysis buffer (0.3 g/ml); 1 mg/ml lysozyme (Novagen, Madison, WI) was added and incubated for 30 min on ice. Benzonase (1 U/ml; Novagen) was added and incubated for an additional 15 min, and then cells were disrupted for 5 ϫ 10 s using an ultrasonicator at 50% output control (Heat Systems-Ultrasonics, Plainview, NY). Cell debris was removed by centrifugation (30 min, 47,000 g); cleared cell lysates were used for protein purification.
Protein purification. The 6ϫ His-tagged 1ϫInlB36-321 and 2ϫInlB36-321 were purified using Ni-NTA Superflow according to the QIAexpressionist protocol (Qiagen, Valencia, CA). Briefly, CellThru 10-ml disposable columns (Clontech Laboratories, Mountain View, CA) were packed by gravity flow with 50% Ni-NTA Superflow (Qiagen, 2.5 ml/column). After equilibration using 20 ml of lysis buffer, the column was loaded with cell lysate and washed with 10 ml of lysis buffer containing 20 and 60 mM imidazole. Proteins were eluted from the column using 10 ml of lysis buffer containing 250 mM imidazole. Fractions from each purification step were analyzed by 10% SDS-PAGE. After identification of fractions containing the InlB protein, the imidazole-eluate was diluted to 1:10 with running buffer (5 mM phosphate buffer, pH 6.8) and loaded to hydroxyapatite column (Bioscale Mini CHT Ceramic Hydroxyapatite Cartridges, 5 ml; BioRad, Hercules, CA) equilibrated with 30 ml of running buffer. The column was washed once with 25 ml of running buffer and subsequently with 25 ml of running buffer containing 1 M NaCl. Proteins were eluted using a linear gradient of phosphate buffer (10 mM, pH 6.0, and 500 mM, pH 7.0; 25 ml each). Fractions from each purification step were analyzed by 10% SDS-PAGE. Amicon Ultra-15 filter units (10 kDa; Millipore) were used according to the manufacturer's instructions to concentrate the purified protein, to remove imidazole, and to reduce salt concentration. Endotoxin was removed from the purified and concentrated protein solution using the DetoxiGel Endotoxin Removal Gel according to the manufacturer's protocol (Pierce Biotechnology, Rockford, IL).
Cell culture. Bovine pulmonary artery endothelial cells (PAEC) were purchased from Cell Applications (San Diego, CA). Passages 2-8 cells were used for all experiments and were cultured in RPMI 1640 (Invitrogen) supplemented with 10% FBS (Gemini, Woodland, CA), 1% penicillin/streptomycin, and 0.5% fungizone (Invitrogen). Cells were grown in 5% CO 2 at 37°C in a humidified atmosphere in a cell culture incubator. 184B5 mammary epithelial cells were grown as previously described (12) . Cells were grown in RPMI 1640 medium (Invitrogen) with 10% FBS (Gemini Bioproducts) with 5 ng/ml epidermal growth factor (BD Biosciences Pharmingen, San Diego, CA) and 1% penicillin/streptomycin. EA.hy926 cells, a human umbilical vein cell line, were purchased from American Type Culture Collection (Manassas, VA) and cultured according to the manufacturer's instructions. Human lung fibroblast (HLuFb) were purchased from Coriell Institute for Medical research (Camden, NJ). Passages 2-5 cells were used for all experiments and were cultured in DMEM medium containing 15% non-heat-inactivated FBS (Gemini Bioproducts), 1% penicillin/streptomycin, and supplemented with 1ϫ NEAA (Invitrogen).
Immunoblotting. Cells were washed once with cold PBS and resuspended in 100 l of 1ϫ SDS lysis buffer (62.5 mM Tris·HCl, pH 6.8, 2% wt/vol SDS, 10% glycerol, 50 mM DTT, and 0.01% bromophenol blue). DNA was sheared using an ultrasonicator (Heat Systems-Ultrasonics, Plainview, NY) at 50% output control for 15 s at 4°C. Samples were heated for 5 min at 95°C. Equal amounts of protein (10 g) for each sample were separated by 10% SDS-PAGE and electroblotted at 20 V for 60 min using a semidry blotting system (BioRad) onto a PVDF membrane. Blots were blocked in 5% BSA in TBS/0.1% Tween 20 (TTBS) for 1 h at ambient temperature before incubating overnight with 1:1,000 dilution of primary antibody in TTBS/0.5% BSA at 4°C. Blots were washed in 3ϫ TTBS for 10 min, for 30 min total. Secondary antibodies (1:1,000 in TTBS) were blotted for 1 h; blots were washed in TBS for at least 2 h before exposing. ECL (Pierce Biotechnology, Rockford, IL) was applied according to the manufacturer's instructions and analyzed on a FujiFilm Image Reader LAS-1000Pro (FujiFilm USA, Valhalla, NY). To normalize for protein loading, blots were stripped using BME Stripping Buffer (10% SDS, ␤-mercaptoethanol, 0.5 M Tris·HCl) and reblotted for ␤-actin.
Electrochemiluminescent assays of Met content and activated (phospho-) Met. Met protein content was measured using a two-site electrochemiluminescent immunoassay developed for use with a SectorImager 2400 plate reader (Meso Scale Discovery, Gaithersburg, MD) as described previously (1) . Antibodies for capture (BAF-358) and detection (AF-276) were obtained from R&D Systems (Minneapolis, MN). Detection antibodies were tagged with a ruthenium chelate (MSD Sulfo-Tag) per the manufacturer's instructions; in the presence of appropriate redox reagents, the tag emits light when current is applied to the multiwell plate, and this light is measured by the SectorImager CCD camera. Use of a purified recombinant Met ectodomain-Ig fusion protein (358-MT, R&D Systems) as a reference standard permits quantitation as Met mass per mass total extracted cell protein. Met autophosphorylation in cell lysates was measured using the same capture antibody followed by detection with anti-phosphotyrosine antibody 4G10 (Millipore). For time course experiments of Met activation and degradation, cultured cells (184B5 or EA.hy926, respectively) were serum deprived for 48 h and stimulated with HGF or InlB fragments for the indicated time periods. The cells were lysed with ice-cold buffer containing non-ionic detergent, protease, and phosphatase inhibitors; cleared extracts were applied to plates containing immobilized Met capture antibody and with anti-Met, and, in parallel, anti-pY, as described above. All measurements were made on triplicate samples, and results shown are representative of three or more independent experiments. GraphPad Prism 5 software was used for regression analyses and ANOVA.
Neutral comet assay. The neutral comet assay was used to measure double-stranded DNA breaks as an indication of apoptosis as previously described (28) . PAEC were either control or treated with Ang II to stimulate apoptosis Ϯ 20 min pretreatment with the InlB36-321 monomer, the InlB36-321 dimer, or HGF. After 16 h, cells were harvested, counted, and embedded in 1% low-melting point agarose (Sigma) and placed on a comet slide (Trevigen, Gaithersburg, MD). Slides were then placed in lysis solution (2.5 M NaCl, 1% sodium lauryl sarcosinate, 100 mM EDTA, 10 mM Tris base, 0.01% Triton X-100) for 15 min and then washed by immersion in 1ϫ Tris/borate/ EDTA buffer (TBE; 0.089 M Tris, 0.089 M boric acid, and 0.002 M EDTA, pH 8.0). The nuclei were subsequently electrophoresed for 10 min at 18 V/cm in 1ϫTBE. Slides were fixed in 75% ethanol for 10 min and air-dried overnight. Cells were then stained with 1ϫ Sybr Green (Molecular Probes, Eugene, OR). Immediately after staining, comets were visualized with an Olympus FV500 series confocal laser scanning microscope using ϫ20 magnification at 478-nm excitation and 507-nm emission wavelengths. Between 100 and 150 comets from random fields were scored per experiment and assigned into type A, B, or C categories, based on their tail moments. Type C comets were defined as apoptotic cells as described by Krown et al. 1996 (30) .
DNA laddering assay. PAEC were harvested in the medium and pelleted at 1,000 g. Pellets were resuspended on ice in lysis buffer (10 mM Tris, 1 mM EDTA, 0.2% Triton, pH 8.0) for 15 min. Cell debris and intact nuclei were removed by centrifugation at 15,000 g for 15 min at 4°C. RNA was removed by RNase A (0.06 mg/ml) incubation for 30 min at 37°C. Then, SDS (final concentration at 0.5%) and 0.15 mg/ml of proteinase K were added to the lysate and incubated overnight at 50°C. DNA fragments were precipitated by the addition of 0.1 volume of 5 M NaCl and 1 volume of isopropanol on ice for 10 min. After centrifugation for 15 min at 15,000 g, DNA fragments were dissolved in 20 l of TE buffer. GelPilot DNA Loading Dye (4 l, Qiagen) was added to this solution and incubated for 10 min at 50°C, and then the DNA was analyzed by 1.5% agarose gel electrophoresis at 20 V for 2 h.
TUNEL assay. PAEC were grown to 80% confluency in 35-mm dishes and treated at indicated time points. TUNEL assay was then performed using Promega DeadEnd Fluorometric TUNEL Assay kit following the manufacturer's protocol.
Cell growth assay. PAEC were seeded at a density of 5 ϫ 10 4 cells/35 mm dish. To attached cells, HGF, the InlB36-321 monomer, or the InlB36-321 dimer was added in triplicate wells to the medium on days 1, 2, 4, 6, and 8. Cells were trypsinized and counted in triplicate using a hemacytometer at the indicated time points. Migration assay. PAEC were trypsinized, washed, and plated at a density of 3 ϫ 10 5 cells/well in 12-well/plate Transwell (Corning, Corning, NY) dishes (12-m pore size). Cells were allowed to attach for 3 h and were then treated in both upper and lower chambers with HGF, the InlB36-321 monomer, or the InlB36-321 dimer in triplicate wells. After 16 h, cells migrated through the Transwell insert were fixed for 15 min in 100% methanol and stained for 1 h in 0.94% crystal violet (Fisher, Fairlawn, NJ) in 20% methanol. The insert was rinsed in a large volume of H2O, and the upper side of the membrane was cleaned using a cotton swab. Remaining migrated cells were counted by microscopy.
Animals and ex vivo cultures. All treatment of animals was performed according to National Institutes of Health, Department of Defense, and with institutional IACUC approval. Sprague-Dawley rats (Taconic, Germantown, NY) were housed, 1 female with litter per cage, in a facility accredited by the Association for Assessment and Accreditation of Laboratory Animal Care International. Animal rooms were maintained at 21 Ϯ 2°C, 50% Ϯ 10% humidity, and 12-h light/dark cycle. Commercial rodent ration (Harlan Teklad Rodent Diet 8604) and water were freely available. Rat pups were obtained on postnatal days 10 -11 . Animals were anesthetized with pentobarbital and decapitated or euthanized with Fatal-Plus. The surface of the anterior chest wall and upper abdomen were sterilized with 70% ethanol. After the trachea was exposed, a small nick was made to insert a 22-gauge needle with a short piece of polyethelene tube attached. Two lines were tied around the trachea to stabilize and to prevent the tube from slipping out. Through a midline abdominal incision, the chest cavity was exposed, and the animal was exsanguinated by dissecting the abdominal aorta. The right ventricle was punctured, and the lungs were perfused with sterile PBS to remove the blood. Using aseptic technique, the trachea, lungs, and the heart were dissected from the animal. To obtain lung slices for the ex vivo culture, the lungs were inflated with 1% low-melting point agarose dissolved in RPMI medium. Agarose was instilled as a liquid into the trachea using a syringe and to fully inflate the lungs. The lungs were placed in sterile cell culture plates and at 4°C for at least 30 min to solidify the agarose. The heart was then excised from the lung, and each lobe of the lungs was embedded in 1% agarose. The agarosefilled and embedded lungs were then chopped on a McIlwain tissue chopper (GeneQ Quebec, Canada) into 500-m-thick slices. The lung explant slices were incubated in RPMI 1640 containing 10% FBS, 1% penicillin/streptomycin, and 0.5% fungizone for 1 h at 37°C in a humidified chamber with 5% CO 2. Lung slices were then transferred to the wells of a 24-well cell culture plate with treatments performed in triplicate for 16 h.
Statistical analysis. Means Ϯ SD were calculated, and statistically significant differences between two groups were determined by the Student's t-test. For three or more groups, statistical analysis was performed using one-way ANOVA, followed by Bonferroni postanalysis, as appropriate; P Ͻ0.05 was considered statistically significant. Statistical software for all analysis was SigmaStat 3.1 (Point Richmond, CA). 36 -321 and the 2ϫInlB 36 -321 . The fragment of the InlB protein from amino acids 36 to 321 was previously demonstrated to bind and partially activate the Met receptor in transformed mammalian cells (48) . We cloned this portion of the InlB protein with a 6-His tag for purification as a monomer (1ϫInlB 36 -321 ) and as a tandem repeat with a linker peptide (2ϫInlB 36 -321 ). The proteins were expressed in E. coli, purified on a Ni-NTA column, and treated for the removal of endotoxin. The purified InlB 36 -321 monomer resulted in a protein of 32 kDa, whereas the purified 2ϫInlB 36 -321 resulted in a 65-kDa protein (Supplementary Data, Fig. S1 . Supplemental Material for this article is available online at the Journal website).
RESULTS

Differential signal transduction by the 1ϫInlB
We confirmed that the purified recombinant proteins activated the Met receptor kinase using a human mammary epithelial cell line, 184B5, which has relatively high Met protein levels, and with serum deprivation, displays very low basal Met kinase activity and robust activation by HGF (7, 12) . We determined in 184B5 cells that the EC 50 concentrations for Met activation are 0.25 nM, 1.0 nM, and 5.0 nM for HGF, 2ϫlnlB 36 -321 , and 1ϫlnlB 36 -321 , respectively (data not shown). For time course experiments, ligands were used at concentrations determined to provide maximal receptor activation. The time courses of Met activation were determined using nonlinear regression analysis and have R 2 values of 0.9413, 0.9363, and 0.9277 for HGF, 1ϫInlB 36 -321 , and 2ϫInlB 36 -321 , respectively (Fig. 1A) . A two-way ANOVA shows that the InlB 1ϫ and 2ϫ curves are significantly different (20.04% total variance; P Ͻ 0.0001). Although 2ϫInlB 36 -321 reaches an initial maximum that is higher than that observed for HGF, it was used at sixfold greater molar concentration. Two-way ANOVA of these curves yields a 14.07% variance overall (P Ͻ 0.0001). The analysis suggests that the rates of Met activation by HGF and 2ϫInlB 36 -321 are similar, whereas that for 1ϫInlB 36 -321 is slower by comparison. All three ligands achieved a similar sustained level of Met activation after 60 min. These results confirm Met binding and activation by both InlB 36 -321 proteins and are consistent with a prior report of increased potency associated with dimeric form of InlB 36 -321 (8) .
Met degradation experiments were performed using the human hybrid vascular endothelial cell line EA.hy926. This cell line was selected for analysis of Met degradation because it has a relatively low level of Met protein, and ligand-driven changes in receptor abundance are readily measured. The time courses of Met protein content change in response to ligand stimulation are shown in Fig. 1B . Concentrations of ligands are the same as in Fig. 1A . The curves were determined using nonlinear regression analysis and have R 2 values of 0.9693, 0.9809, and 0.9842 for HGF, 1ϫInlB , and 2ϫInlB , respectively. Similar to the Met activation profiles, the results show that the rates of Met degradation driven by HGF and 2ϫInlB 36 -321 are similar, whereas that for 1ϫInlB 36 -321 is slower by comparison. The initial difference in HGF and 2ϫ InlB 36-321 degradation maxima is less than that observed in activation experiments, consistent with the slower rate of change overall and the greater complexity of degradation compared with Met activation. Although all three ligands reduce Met content significantly after 24 h, a two-way ANOVA shows that the 1ϫInlB 36 -321 and 2ϫInlB 36 -321 curves are significantly different (18.4% total variance; P Ͻ
Fig. 1. Temporal profiles of ligand-stimulated Met activation and degradation.
A: Met activation, expressed as phosphoMet signal intensity units normalized to Met protein and total cellular protein (SI/ng/mg), in 184B5 normal human epithelial cells stimulated with HGF (circles), 1ϫInlB36-321 (squares), or 2ϫInlB36-321 (triangles). Ligands were used at concentrations determined to provide maximal receptor activation at 20 min: 1.0 nM, 12.5 nM, and 6.1 nM for HGF, 1ϫInlB36-321, and 2ϫInlB36-321, respectively. Significant differences among the curves were determined using 2-way ANOVA and are discussed in the text. B: Met degradation, expressed as Met normalized to total protein (ng/mg) in EA.hy926 human hybrid vascular endothelial cells stimulated with HGF (circles), 1ϫInlB36-321 (squares), or 2ϫInlB36-321 (triangles). Ligands were used at concentrations listed in A. Significant differences among the curves were determined using 2-way ANOVA and are discussed in the text. 0.0001). Similar analysis of the HGF and 2ϫInlB 36 -321 curves reveals 2.44% total variance between the curves, which, while statistically significant, yields only a 10% difference in Met abundance from 8 to 24 h; the HGF and 1ϫInlB 36 -321 curves have a fourfold higher total variance of 9.92% (P Ͻ 0.0001), but ultimately converge after 24 h.
Each of the purified InlB 36 -321 proteins was used to treat primary PAEC to compare signal transduction pathway activation in nontransformed, non-immortalized cells. We compared activation of ERK1/2 MAPK, Akt, and STAT3 by HGF and the two InlB constructs, as these three pathways have been implicated in HGF-induced proliferation (10, 44) . We previously determined that maximal ERK1/2 activation occurred within 5-30 min by HGF and the InlB constructs in PAEC (35) . Western blots showed that within 15 min, phospho-ERK1/2 increased by threefold and fivefold following exposure to 1.2 or 2.5 nM HGF, respectively ( Fig. 2A) . Treatment with 0.3, 1.0, or 5.0 nM 2ϫInlB 36 -321 resulted in twofold, twofold, and fourfold increases in phospho-ERK, respectively. In contrast, treatment with 0.3 nM 1ϫInlB 36 -321 had no significant effect on ERK activation. Treatment with 1.0 and 5.0 nM 1ϫInlB 36 -321 induced twofold and fourfold increases in ERK activation, similar to the level of activation by 2ϫInlB 36 -321 .
The PI3K/Akt pathway has been shown to be required for cellular proliferation by HGF (12) . Akt activation is associated with its phosphorylation. Within 15 min of treatment with HGF, an approximately twofold increase in phospho-Akt was observed (Fig. 2B) . Treatment with 0.6 nM 2ϫInlB 36 -321 resulted in a 50% increase in phospho-Akt within 15 min and a twofold increase at 30 min. Treatment with 6.0 nM 2ϫInlB 36 -321 provided a 2-fold and 2.4-fold increase in phospho-Akt at 15 and 30 min, respectively. Activation of Akt by 10 nM 1ϫInlB 36 -321 was not detected at any time point (Fig.  2B) , even though this concentration of 1ϫInlB 36 -321 was sufficient to induce ERK1/2 phosphorylation. STAT3 activation by HGF has been shown to participate in cellular proliferation in tissue repair (44) . HGF induced a ϳ12-fold increase in phosphorylation within 15 min (Fig. 2C) . Treatment with 2ϫInlB 36 -321 for 30 min (both 0.6 and 6 nM) induced similar levels of STAT3 phosphorylation as HGF. However, although 1ϫInlB 36 -321 significantly activated STAT3, maximal levels were only fivefold above control levels. Together, these results suggest that 0.6 nM 2ϫInlB 36 -321 induced significant phosphorylation of all three Met signaling molecules, ERK1/2, Akt, and STAT3, at levels similar to HGF. In contrast, the 1ϫInlB 36 -321 activates Met, but subsequent signaling is weaker than that of 2ϫInlB 36 -321 .
Cell motility and cell survival by 2ϫInlB 36 -321 compared with 1ϫInlB 36 -321 . Cell motility is an important activity induced by HGF through Met activation. Previous reports demonstrated that InlB 36 -321 induced migration in transformed cell types (48) . We compared motility in PAEC induced by both the 1ϫInlB 36 -321 and 2ϫInlB 36 -321 . Levels of migration in control cultures were 60 Ϯ 5 (Fig. 3) . HGF induced significant increase of motility (123 Ϯ 7, P Ͻ 0.05). The 2ϫInlB 36 -321 induced cell migration equivalent to that induced by full-length HGF (133 Ϯ 10), which was significantly higher than migration induced by the 1ϫInlB 36 -321 (89 Ϯ 14; P Ͻ 0.05 compared with 2ϫInlB 36 -321 ; Fig. 3 ). Our laboratory recently demonstrated that Ang II, a profibrotic peptide, activates intrinsic apoptosis (34) , and bleomycin, a chemotherapeutic agent that induces lung fibrosis in humans and animal models, activates the extrinsic pathway of apoptosis in PAEC (43) . We examined the cell survival activity of both 1ϫand 2ϫInlB 36 -321 . HGF reduced apoptosis to 11% Ϯ 0.9, P Ͻ 0.05, compared with Ang II alone, and 2ϫInlB 36 -321 (6.0 and 0.6 nM) provided protection at a similar level with HGF as determined by the Neutral Comet assay (Fig. 4A) . Both HGF and 2ϫInlB 36 -321 also provided similar levels of cell survival (ϳ5% apoptosis, P Ͻ 0.05) as determined by the TUNEL assay (Fig. 4B) . Pretreatment of cells for 1 h with 10 nM 1ϫInlB 36 -321 also resulted in significant protection of PAEC from Ang II-induced DNA fragmentation as determined by Comet assay, but to a lesser extent compared with the other ligands (32% Ϯ 0.4, P Ͻ 0.05 from Ang II alone). However, TUNEL assay showed that treatment with 10 nM 1ϫInlB 36 -321 provided levels of cell survival similar to that of the other ligands (Fig. 4B) . The addition of HGF or either InlB 36 -321 peptide alone did not statistically alter the apoptosis from basal levels in either assay. Together, these data suggest that 1ϫInlB 36 -321 and 2ϫInlB 36 -321 provide similar levels of anti-apoptotic activity.
To confirm the anti-apoptotic activity of 2ϫInlB 36 -321 , we conducted apoptosis-specific DNA laddering assays. Treatment of PAEC with Ang II or bleomycin resulted in DNA laddering within 16 h (Fig. 4C) . Treatment of cells with 2ϫInlB 36 -321 for 20 min before apoptosis stimulation completely prevented DNA laddering induced by both Ang II and bleomycin. Together, these data demonstrate that the InlB 36 -321 proteins, like HGF, promote cell survival from Ang II.
The 2ϫInlB 36 -321 induces proliferation in primary lung endothelial cells. Because the InlB dimer activates PI3K/Akt and STAT3 in addition to ERK1/2, three signaling pathways that are involved in proliferation by Met (12), we examined cell growth in primary endothelial cells. In agreement with findings by others (47), we found that 1ϫInlB 36 -321 failed to induce proliferation in PAEC (Fig. 5) . However, 2ϫInlB 36 -321 induced proliferation equivalent to that induced by HGF (Fig.  5) . Together with the prior results, these findings suggest that in PAEC, activating the ERK1/2 cascade without activating the PI3K/Akt axis is sufficient for a motogenic but not mitogenic response to Met activation.
The 2ϫInlB 36 -321 activates cell survival in ex vivo lung tissue. A number of studies have utilized ex vivo lung cultures as substitutes for in vivo models. This technique has the advantage of allowing lung-specific assessments from potentially confounding whole body effects (21) . Because an isolated organ experiment sustains the architecture and functionality of the tissue, it represents a closer model to in vivo than the in vitro models from a single cell type. Studies have shown that alveolar cells spontaneously divide and correctly differentiate in ex vivo lung slice cultures (26) , and this technique has been used to determine drug responses, apoptosis, and cell survival (18, 32, 36) . The ex vivo lung model has been demonstrated to act as a reliable model for in vivo studies to demonstrate the role of Ang II signaling in lung cell apoptosis from profibrotic stimuli (36, 38) . To determine whether the InlB 36 -321 can protect cells in lung from Ang II-induced apoptosis, we examined caspase 3 activation in rat ex vivo lung slices cultured in the presence or absence of HGF, 1ϫ, or 2ϫInlB 36 -321 . Caspase 3 was activated by the addition of Ang II within 16 h as shown by Western blot using specific antibodies (Fig. 6 ). HGF and both InlB 36 -321 peptides suppressed caspase 3 activation significantly to near baseline levels. Compared with 1ϫInlB 36 -321 , 2ϫInlB 36 -321 was able to inhibit caspase 3 activation at 10-fold lower concentration (Fig. 6) . None of the ligands activated caspase 3 when applied in the absence of Ang II.
Activation of ERK1/2 by InlB 36 -321 is cell type specific. Our results suggested that the InlB 36 -321 peptides activate HGF receptor Met and its downstream signaling, and we wanted to verify that the activity of the InlB 36 -321 was Met-specific. Met is predominantly expressed in cells from epithelial origin, whereas expression of HGF was usually restricted to cells of mesenchymal origin (53) . Therefore, we used Met-negative fibroblast cells to evaluate the specificity of ERK1/2 activation in response to both InlB 36 -321 peptides and HGF. As expected, both 1ϫInlB 36 -321 and 2ϫInlB 36 -321 activated ERK1/2, similarly to HGF, within 15 min of treatment in PAEC (Fig. 7A ), but not in primary fibroblast cultures that do not express Met (Fig. 7B) . As a positive control, we show that EGF activates ERK1/2 in primary fibroblast cultures (Fig. 7) .
DISCUSSION
Here we show that a fragment of the L. monocytogenes InlB, amino acids 36 -321 (1ϫInlB 36 -321 ), activates the ERK1/2 and STAT3 pathways in primary lung endothelial cells, resulting in motility, as well as cell survival from Ang II-induced apoptosis. Expression of the InlB 36 -321 as a modified tandem repeat (2ϫInlB 36 -321 ) results in the activation of an additional pathway, the PI3K/Akt pathway. Cell growth and cell migration assays showed improved activity of 2ϫInlB 36 -321 compared with the 1ϫform. We propose that this additional signal transduction pathway is correlated with improved motility compared with 1ϫInlB 36 -321 , as well as with the added biological activity of cell proliferation in PAEC cultures. Our results using ex vivo lung slices represent an alternative to in vivo methods in measuring cellular signaling mechanisms. Therefore, our findings of protection from Ang II-induced apoptosis in our lung slice cultures by 1ϫInlB 36 -321 may be considered predictive for the activity of this protein in vivo.
HGF signaling through the Met receptor induces normal tissue repair in a manner that restores tissue structure and prevents the development of extensive scar formation or fibrosis in liver, kidney, heart, brain, and lung (27, 40, 41, 46, 59, 66, 67) . The importance of HGF in tissue repair and the cost and difficulty associated with producing recombinant, active HGF protein has prompted researchers to seek alternative means to activate the pathway, such as inducing endogenous HGF gene expression and protein production using natural and synthetic compounds (45, 51, 60) or using exogenous expression methods. However, HGF has been shown to be an important factor in the progression of tumorigenesis, discouraging the treatment of human patients with HGF in retroviral systems that would induce its permanent or constitutive expression. Instead, transient, nonviral in vivo gene transfer techniques have been investigated and demonstrated to be effective in a variety of animal models of organ fibrosis (11, 19, 51, 56, 65, 67) . These methods are currently being tested in early clinical trials for HGF exogenous expression (42) .
Studies suggest that the ERK1/2, PI3K/Akt, and the STAT3 pathways are required for the mitogenic activity of HGF (10) . HGF-stimulated mitogenesis seems to depend on duration of ERK1/2 activation in some cell types (12) . In others, both ERK1/2 and STAT3 activation are needed for cell proliferation (44) . Our data using the InlB peptides suggest that ERK1/2 and STAT3 activation are not sufficient for mitogenesis in PAEC downstream of Met activation and that the PI3K/Akt pathway is also required.
We propose that the novel 2ϫInlB 36 -321 may have therapeutic potential similar to that of full-length HGF. Additionally, treatment using 2ϫInlB 36 -321 has potential advantages over the use of HGF protein for wound repair. One complication for the use of HGF protein is that HGF must be activated by cleavage at R494 by an extracellular protease on the target cell (53) . This additional requirement for processing of HGF to its active form has implications for the use of a cytokine or other agent to stimulate HGF production, since stimulation of HGF production doesn't ensure that it will be active in the vicinity of the target cell. In contrast, the 2ϫInlB 36 -321 is synthesized in its active form. A second complication of the use of HGF is that HGF is a potent factor in cancer progression (13) . In contrast, a recent report indicates that InlB protein binding to Met downregulates the receptor on the surface of cancer cells (16) , and it has been proposed that InlB and its fragments may be useful for suppression of Met signaling in cancer (9) . Our cell culture studies of Met downregulation suggest that HGF and 2ϫInlB 36 -321 are similar, whereas that for 1ϫInlB 36 -321 is slower by comparison.
It is widely viewed that tyrosine kinase receptors are activated by dimerization, but that multiple mechanisms have evolved to induce the active dimeric state (55) . For the Met receptor, dimers have been observed of truncated versions of the receptor with ligands in crystal structures (15, 17) . Cell culture data has indicated that Met clustering does occur in cells during Met activation (14) , but discrete dimers of fulllength Met have not yet been demonstrated in intact cells. A recent study by Ferraris et al. (15) described signaling and biological activities in cancer cells of an InlB dimer that was engineered using a disulfide bond centered on the convex face of the LRR helix, allowing the formation of an antiparallel arrangement of two InlB 36 -321 fragments. This construct differs significantly from the construct used in the present work, which provides a head-to-tail arrangement of the InlB 36 -321 fragments. The structural differences between the two InlB constructs have significant implications for the physical mechanism of Met receptor activation, which has eluded full characterization for two decades by virtue of its complexity. Our findings together with those of Ferraris et al. suggest that both the antiparallel dimer and tandemly repeated InlB 36 -321 fragment are sufficient to induce Met dimerization and/or clustering. A better understanding of the mechanism of Met receptor activation may facilitate the improvement of both inhibitors and agonists for this important signaling pathway.
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We thank Dr. Suzanne B. Bausch and W. Brad Rittase (USUHS, Bethesda, MD) for supplying rat lung tissue and for help in development of the ex vivo slice culture technique. We also thank Dr. Laurel Lenz for his gift of genomic DNA from Listeria. fibroblasts. Cells were grown to 80% confluence and placed overnight in starving media containing 0.01% FBS. They were then treated with 1ϫ(10 Ϫ8 M), 2ϫInlB36-321 (6 ϫ10 Ϫ10 M), or HGF (3 ϫ10 Ϫ10 M) for 15 min. Cell lysates were used for Western blot with anti-phospho-ERK1/2. Blots were stripped and reblotted for total ERK for normalization. EGF (100 ng/ml) was used as control. A: ERK1/2 activation in PAEC. B: ERK1/2 activation in primary human lung fibroblast cell culture. Bar graphs show the means Ϯ SD from 3 independent experiments. *P Ͻ 0.05 from control. Representative blots are shown.
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